Analysts at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Stock Performance
CPIX opened at $1.53 on Thursday. Cumberland Pharmaceuticals has a 52-week low of $1.38 and a 52-week high of $2.36. The firm has a market capitalization of $21.71 million, a PE ratio of -2.59 and a beta of 0.23. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.21 and a current ratio of 1.37. The business’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.78.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last released its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The company had revenue of $8.50 million for the quarter.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
- Five stocks we like better than Cumberland Pharmaceuticals
- What Are the FAANG Stocks and Are They Good Investments?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- How to Invest in Small Cap Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Investing In Preferred Stock vs. Common Stock
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
